CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.

ABSTRACT: High-grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy due to the lack of reliable biomarkers, effective treatment, and chemoresistance. Improving the diagnosis and the development of targeted therapies is still needed. The molecular pathomechanisms driving HGSC progression are not fully understood though crucial for effective diagnosis and identification of novel targeted therapy options. The oncogene CTCFL (BORIS), the paralog of CTCF, is a transcriptional factor highly expressed in ovarian cancer (but in rarely any other tissue in females) with cancer-specific characteristics and therapeutic potential. In this work, we seek to understand the regulatory functions of CTCFL to unravel new target genes with clinical relevance. We used in vitro models to evaluat

SUBMITTER: Salgado-Albarran M 

PROVIDER: S-EPMC8821627 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature